Free tool
FAERS Monitor: Eraxis
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021632 or its brand name (Eraxis, Anidulafungin). Reports on generic versions are filed under their own applications.
Reports
1,627
Serious
1,582
97% of reports
Hospitalization
779
Death reported
692
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective393
- off label use187
- multiple organ dysfunction syndrome174
- septic shock128
- sepsis118
- pneumonia94
- candida infection92
- pyrexia92
- neutropenia85
- death80
- drug resistance72
- condition aggravated70
- renal failure69
- respiratory failure65
- hypotension58
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2006 | 8 |
| 2007 | 18 |
| 2008 | 12 |
| 2009 | 24 |
| 2010 | 36 |
| 2011 | 47 |
| 2012 | 28 |
| 2013 | 24 |
| 2014 | 22 |
| 2015 | 21 |
| 2016 | 52 |
| 2017 | 70 |
| 2018 | 118 |
| 2019 | 122 |
| 2020 | 123 |
| 2021 | 138 |
| 2022 | 189 |
| 2023 | 174 |
| 2024 | 157 |
| 2025 | 145 |
| 2026 | 99 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,532 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| multiple organ dysfunction syndromeSignal | 174 | 79.9 | 69.4 | 13,412 |
| candida infectionSignal | 92 | 70.8 | 58.0 | 6,233 |
| septic shockSignal | 128 | 38.1 | 32.3 | 4,589 |
| drug resistanceSignal | 72 | 36.3 | 29.0 | 2,435 |
| sepsisSignal | 118 | 13.7 | 11.5 | 1,381 |
| respiratory failureSignal | 65 | 11.5 | 9.1 | 616 |
| neutropeniaSignal | 85 | 8.1 | 6.6 | 524 |
| renal failureSignal | 69 | 6.7 | 5.3 | 332 |
| drug ineffectiveSignal | 393 | 3.9 | 3.5 | 884 |
| pneumoniaSignal | 94 | 3.8 | 3.1 | 190 |
| hypotensionSignal | 58 | 3.7 | 2.9 | 115 |
| pyrexiaSignal | 92 | 3.4 | 2.8 | 159 |
| condition aggravatedSignal | 70 | 3.0 | 2.4 | 91 |
| off label useSignal | 187 | 2.8 | 2.4 | 217 |
| death | 80 | 1.2 | 1.0 | 3 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.